NeuroWiki Progress

NeuroWiki Progress

Overview

NeuroWiki Progress is a topic within the NeuroWiki knowledge base covering aspects of neurodegenerative disease research and mechanisms. NeuroWiki serves as a comprehensive, mechanistically-focused knowledge base for neurodegenerative diseases, with particular emphasis on Alzheimer's disease (AD) and Parkinson's disease (PD), while extending coverage to related disorders including ALS, frontotemporal dementia (FTD), Huntington's disease, and atypical parkinsonian syndromes.

Neurodegenerative diseases represent a class of disorders characterized by progressive loss of neuronal structure and function, leading to cognitive decline, motor impairment, and eventual death [1](https://pubmed.ncbi.nlm.nih.gov/37289896/). These conditions affect millions worldwide, with Alzheimer's disease alone affecting over 55 million people globally, a number projected to reach 139 million by 2050 [2](https://pubmed.ncbi.nlm.nih.gov/38012409/).

Last Updated: 2026-03-21 08:04 PT

Neurodegenerative Disease Research Background

Shared Mechanisms in Neurodegeneration

Despite clinical heterogeneity, neurodegenerative diseases share common pathogenic mechanisms including protein misfolding and aggregation, mitochondrial dysfunction, oxidative stress, neuroinflammation, and impaired autophagy [3](https://pubmed.ncbi.nlm.nih.gov/38514123/). Understanding these shared pathways is critical for developing disease-modifying therapies that may benefit multiple conditions.

NeuroWiki Progress

Overview

NeuroWiki Progress is a topic within the NeuroWiki knowledge base covering aspects of neurodegenerative disease research and mechanisms. NeuroWiki serves as a comprehensive, mechanistically-focused knowledge base for neurodegenerative diseases, with particular emphasis on Alzheimer's disease (AD) and Parkinson's disease (PD), while extending coverage to related disorders including ALS, frontotemporal dementia (FTD), Huntington's disease, and atypical parkinsonian syndromes.

Neurodegenerative diseases represent a class of disorders characterized by progressive loss of neuronal structure and function, leading to cognitive decline, motor impairment, and eventual death [1](https://pubmed.ncbi.nlm.nih.gov/37289896/). These conditions affect millions worldwide, with Alzheimer's disease alone affecting over 55 million people globally, a number projected to reach 139 million by 2050 [2](https://pubmed.ncbi.nlm.nih.gov/38012409/).

Last Updated: 2026-03-21 08:04 PT

Neurodegenerative Disease Research Background

Shared Mechanisms in Neurodegeneration

Despite clinical heterogeneity, neurodegenerative diseases share common pathogenic mechanisms including protein misfolding and aggregation, mitochondrial dysfunction, oxidative stress, neuroinflammation, and impaired autophagy [3](https://pubmed.ncbi.nlm.nih.gov/38514123/). Understanding these shared pathways is critical for developing disease-modifying therapies that may benefit multiple conditions.

Protein aggregation is a hallmark of most neurodegenerative disorders. In Alzheimer's disease, amyloid-beta plaques and tau neurofibrillary tangles accumulate in the brain [4](https://pubmed.ncbi.nlm.nih.gov/37289896/). In Parkinson's disease and related disorders, alpha-synuclein forms Lewy bodies [5](https://pubmed.ncbi.nlm.nih.gov/37289896/). ALS features TDP-43 aggregates, while Huntington's disease involves mutant huntingtin protein expansion [6](https://pubmed.ncbi.nlm.nih.gov/38514123/).

The classification of neurodegenerative diseases has evolved significantly, with emerging genetic, neuropathological, and clinical criteria enabling more precise diagnoses [7](https://pubmed.ncbi.nlm.nih.gov/38871023/). This progress has important implications for clinical trial design and therapeutic development.

Alzheimer's Disease

Alzheimer's disease is the most common cause of dementia, accounting for 60-80% of all dementia cases [8](https://pubmed.ncbi.nlm.nih.gov/38272802/). The disease progresses from subtle memory deficits to severe cognitive impairment, with neuropathological changes beginning decades before clinical symptoms manifest.

Key pathological features include:

• Amyloid plaques: Extracellular deposits of Aβ peptides derived from amyloid precursor protein (APP) cleavage
• Neurofibrillary tangles: Intracellular aggregates of hyperphosphorylated tau protein
• Synaptic loss: Early and progressive loss of synaptic connections
• Neuronal death: Progressive loss of neurons in hippocampus and cortical regions

Parkinson's Disease

Parkinson's disease is the second most common neurodegenerative disorder, affecting approximately 10 million people worldwide [9](https://pubmed.ncbi.nlm.nih.gov/38272802/). The disease is characterized by motor symptoms including resting tremor, bradykinesia, rigidity, and postural instability, while non-motor symptoms encompass cognitive impairment, depression, sleep disorders, and autonomic dysfunction.

Pathologically, Parkinson's disease is characterized by:

• Lewy bodies: Intraneuronal inclusions containing alpha-synuclein
• Loss of dopaminergic neurons: Particularly in the substantia nigra pars compacta
• Lewy body pathology: Progressing from brainstem to cortical regions in a characteristic pattern

Other Neurodegenerative Disorders

Amyotrophic Lateral Sclerosis (ALS) is a rapidly progressive motor neuron disease characterized by muscle weakness, atrophy, and respiratory failure. Genetic factors, including C9orf72, SOD1, FUS, and TARDBP mutations, account for approximately 10-15% of cases [10](https://pubmed.ncbi.nlm.nih.gov/37162014/).

Frontotemporal Dementia (FTD) encompasses a group of disorders characterized by progressive degeneration of the frontal and temporal lobes, leading to behavioral changes and language deficits. The disease shares significant overlap with ALS in terms of genetics and pathology.

Huntington's Disease is an autosomal dominant disorder caused by CAG repeat expansion in the huntingtin gene, leading to progressive motor, cognitive, and psychiatric symptoms.

Task Completion Trend (Last 30 Days)

| Date | Completions |
|------|-------------|
| 2026-03-19 | 7 |
| 2026-03-20 | 622 |
| 2026-03-21 | 142 |

Summary:

• Last 7 days: 20 completions
• Last 30 days: 771 completions
• Daily average: 25.7 completions/day

Tasks by Type

| Type | Total |
|------|-------|
| one-shot | 3 |
| one_shot | 775 |
| recurring | 67 |

Tasks by Priority and Status

| Priority | Open | Done |
|----------|------|------|
| P0 (90+) | 32 | 258 |
| P1 (70-89) | 21 | 451 |
| P2 (50-69) | 15 | 37 |
| P3 (<50) | 6 | 25 |

Velocity Metrics

| Metric | Value |
|--------|-------|
| Completed (7 days) | 771 |
| Completed (30 days) | 771 |
| Created (7 days) | 845 |
| Avg completion time | 0.0 days |

Progress Indicators

• Completion Rate (7d): 771 tasks/week
• Backlog: 74 open tasks
• In Progress: 0 running tasks

Notes

• Progress metrics are derived from Orchestra task database
• One-shot tasks: typically P0-P1 priority, executed once
• Recurring (CI) tasks: maintenance, quality checks, content updates

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References